Date:4/30/2009

--------------------------- A conference call to discuss these financial results will be held today, Thursday April 30, 2009 at 8:00 AM PT (11:00 AM ET). Dial-in information: North America (toll-free): (800) 901-5247 International: (617) 786-4501 Enter Passcode: 72734002 An archived replay of the call will be available until May 7, 2009. North America (toll-free): (888) 286-8010 International: (617) 801-6888 Enter Passcode: 95526962 A live webcast will be available to all interested parties through the Investors section of Angiotech's website: www.angiotech.com ANGIOTECH PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (in thousands of U.S.$, except Three months ended share and per share data) March 31, 2009 ------------------------------------------------------------------------- Reported Adjustment Adjusted REVENUE Royalty revenue $ 17,111 $ - $ 17,111 Product sales, net 46,136 - 46,136 License fees 25,053 (25,053) a - ----------------------------------- ------------------------------------- 88,300 (25,053) 63,247 ----------------------------------- ------------------------------------- EXPENSES License and royalty fees 2,905 - 2,905 Cost of products sold 23,966 - 23,966 Research and development 6,097 (414) b 5,683 Selling, general and administrative 19,572 (2,583) c 16,989 Depreciation and amortization 8,265 (7,381) d 884 I
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter